All articles by Jangoulun Singsit
Jangoulun Singsit
Novavax begins Phase III clinical trial for influenza vaccine NanoFlu
US-based late-stage biotechnology company Novavax has started a pivotal Phase III clinical trial for its influenza vaccine, NanoFlu.
Gilead and Galapagos report data from filgotinib trials in RA
US antiviral drugmaker Gilead Sciences and Belgo-Dutch biotech Galapagos have announced week 52 data from the Phase III FINCH 1 and 3 trials of rheumatoid arthritis (RA) candidate filgotinib.
Anavex initiates ANAVEX 2-73 study in Alzheimer disease
Clinical-stage biopharmaceutical company Anavex Life Sciences has initiated a long-term extension study for patients with early Alzheimer’s disease (AD) and treated with ANAVEX2-73 (blarcamesine).
ESMO 2019: BeiGene presents data on tislelizumab and pamiparib
Biopharmaceutical company BeiGene has presented data on its two investigational drug candidates, anti-PD-1 antibody tislelizumab and PARP inhibitor pamiparib.
Boehringer Ingelheim announces nintedanib trial met its primary endpoint
Boehringer Ingelheim has presented data that shows the Phase III INBUILD trial of nintedanib met its primary endpoint.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
AstraZeneca announces data from BRILINTA independent trial
AstraZeneca has announced that new data from a Phase IV independent trial, TWILIGHT, showed BRILINTA (ticagrelor) monotherapy reduces the possibility of clinically relevant bleeding in high-risk patients who underwent PCI.
Enanta sees topline results of EDP-305 ARGON-1 Phase 2a study for NASH
Biotechnology company Enanta Pharmaceuticals has reported positive results from its ARGON-1 Phase 2a study of its lead product candidate EDP-305 to treat non-alcoholic steatohepatitis (NASH).
Zealand reports results of paediatric Phase 3 trial for hypoglycaemia
Denmark-based biotechnology company Zealand Pharma has reported positive outcome for its dasiglucagon in the paediatric Phase 3 trial for severe hypoglycaemia in diabetes.
Coordination Pharmaceuticals doses first patient in CPI-200 trial
Coordination Pharmaceuticals (CPI) has dosed the first patient in a Phase I study of nanoscale coordination polymer (NCP) CPI-200 in patients with advanced tumours.
Cincinnati Children’s new AI system reduces patient screening time
Researchers at Cincinnati Children’s Hospital Medical Center in the US have designed and tested a new computerised solution which uses artificial intelligence (AI) to effectively identify eligible participants from electronic health records (EHRs).